Open AccessRetrospective Analysis of Clinical Efficacy of Erlotinib in Patients with Non-Small Cell Lung Cancer
Author(s) -
Aylin Ayyıldız
Publication year - 2015
Publication title -
the annals of clinical and analytical medicine
Language(s) - English
Resource type - Journals
ISSN - 2667-663X
DOI - 10.4328/jcam.1991
Subject(s) - medicine , erlotinib , lung cancer , oncology , retrospective cohort study , clinical efficacy , lung , cancer , epidermal growth factor receptor
Aim: In this study, we aimed to evaluate the efficacy and safety of erlotinib as second-, third-, and fourth-line treatment for Turkish patients with advanced non-small cell lung cancer (NSCLC). Material and Method: Thirty-nine patients with advanced, previously treated NSCLC who received 150 mg of erlotinib once daily orally until disease progression or intolerable toxicity were retrospectively analyzed. Results: We observed no complete response, partial responses were observed in 7 (17.9%) patients, and 16 (41%) patients had stable disease. The median progression-free survival was 242 days (95% CI 51-224), and the median overall survival (OS) was 377 days (95% CI 291-462). The median OS of females was significantly better than male patients (470 vs. 271 days, p=0.046). The treatment was generally well tolerated. The most common side effect was skin rash (41%). Discussion: Erlotinib was safe and effective in treating Turkish patients with advanced NSCLC who had been previously treated with the standard chemotherapy